Browsing by Author "Aksoy, Seçil"

Now showing 1 - 8 of 8

Cancer stem cell markers in pancreatic ductal adenocarcinoma
(Oxford Univ Press, 2018-10-01) Aksoy, Fuat; Kaya, Ekrem; Egeli, Ünal; Dündar, Halit Ziya; Taşar, Pınar; Aksoy, Seçil; Özen, Yılmaz; Tunca, Berrin; Çeçener, Gülşah; Yerci, Ömer; AKSOY, FUAT; KAYA, EKREM; EGELİ, ÜNAL; DÜNDAR, HALİT ZİYA; TAŞAR, PINAR; AKSOY, SEÇİL; ÖZEN, YILMAZ; TUNCA, BERRİN; ÇEÇENER, GÜLŞAH; YERCİ, ÖMER; 0000-0002-9562-4195; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Bölümü; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Biyoloji Bölümü; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Bölümü; 0000-0001-5808-9384; 0000-0001-7904-883X; 0000-0002-1619-6680; 0000-0002-3820-424X; 0000-0002-3820-424X; AAH-1420-2021; AAH-3847-2021; ADM-8457-2022; HII-8895-2022; ABI-6078-2020; AAG-7319-2021; EWI-3634-2022; IIC-9825-2023; FOQ-1792-2022; AAP-9988-2020
Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients
(Elsevier Science, 2019-10-14) Eskiler, Gamze Güney; Çeçener, Gülşah; Takanlou, Leila Sabour; Takanlou, Maryam Sabour; Egeli, Ünal; Aksoy, Seçil; Ünal, Ufuk; Tezcan, Havva; Eryılmaz, Işıl Ezgi; Gökgöz, Mustafa Şehsuvar; Tunca, Berrin; Çubukçu, Erdem; Evrensel, Türkkan; Çetintaş, Sibel; Taşdelen, İsmet; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji ve Genetik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; 0000-0002-3820-424X; 0000-0001-7904-883X; 0000-0002-3760-9755; 0000-0003-4913-3616; 0000-0002-3316-316X; 0000-0002-1619-6680; 0000-0002-9732-5340; GGI-6227-2022; EAS-6830-2022; GYU-0252-2022; EWY-5692-2022; ETP-1691-2022; EOI-5652-2022; EBN-1186-2022; 6508156530; 57211585974; 57211582304; 55665145000; 57193933334; 57211584917; 57211580953; 57189380840; 57203870909; 6602965754; 53986153800; 6603942124; 6505881756; 9637821500
The aim of this study was to identify the frequency and spectrum of germline BRCA1/2 pathogenic alterations in a cohort of patients with breast carcinoma. In this study, a total of 603 breast cancer subjects from Turkey were screened for BRCA1/BRCA2 mutations using HDA and Sanger sequencing. In the present study, 21 BRCA1 and BRCA2 pathogenic variants were detected in 30 patients and BRCA1/2 mutations were significantly associated with a family history of breast/ovarian cancer. Analysis of overall survival for BRCA1/BRCA2 mutation carriers showed a trend for poor overall survival only in BRCA1 carriers, although this was not statistically significant in BRCA1 and BRCA2 mutation carriers. The c.5266dupC mutation is one of the most frequently reported mutations in BRCA1 and was identified in five breast cancer patients in our study. The most common BRCA2 gene mutations in the present study were c.8940delA and c.9097dupA, which were found in seven patients. We found mostly BRCA1 and BRCA2 mutation carriers in those patients who showed hormone-positive features. In conclusion, our data showed differences in the distribution of the mutation spectrum of BRCA1 and BRCA2 in Turkey.
Degenerative changes of the mandibular condyle in relation to the temporomandibular joint space, gender and age: A multicenter CBCT study
(Wroclaw Medical Univ, 2023-01-01) Görürgöz, Cansu; İçen, Murat; Kurt, Mehmet Hakan; Aksoy, Seçil; Bakirarar, Batuhan; Rozylo-Kalinowska, Ingrid; Orhan, Kaan; GÖRÜRGÖZ, CANSU; Bursa Uludağ Üniversitesi/Diş Hekimliği Fakültesi/Dentomaksillofasiyal Radyoloji Anabilim Dalı.; 0000-0002-3083-1660 ; AAQ-4576-2020
Background. Cone-beam computed tomography (CBCT) is used to provide multiplanar views of the temporomandibular joint (TMJ) bone components as well as TMJ pathologies without superposition, magnification or distortion.Objectives. The study aimed to analyze degenerative changes in the condylar surface, and their relation-ship with patient age and gender, and the TMJ space measurements by using CBCT images. Material and methods. A total of 258 individuals were retrospectively analyzed. The degenerative bone changes of the condylar head were evaluated and classified on the right and left sides. The shortest dis-tances from the anterior, superior and posterior parts of the condylar head to the glenoid fossa were mea-sured to represent the TMJ space. Univariate and multivariate logistic regression analyses then evaluated the effect of age and gender on the presence of degenerative changes.Results. Condylar flattening was most frequently observed (413 TMJs, 53.5%). However, the presence or absence of the change types did not differ according to the sides. The mean values of the TMJ space measurements on the right and left sides were narrower in the group with changes than in the group without changes. Nonetheless, no statistically significant difference in the TMJ space was found between the groups (p > 0.05).Conclusions. An increased risk of radiographically detectable degenerative alterations in left TMJs was detected for males and for increasing age. Degenerative changes in the condylar surface may affect the dimensions of the TMJ space.
DPYD c.1905+1G>A promotes fluoropyrimidine-induced anemia, a prognostic factor in disease-free survival, in colorectal cancer
(Mary Ann Liebert, Inc, 2021-04-01) Deligönül, Adem; Aksoy, Seçil; Tezcan, Gülçin; Tunca, Berrin; Kanat, Özkan; Çubukcu, Erdem; Yılmazlar, Tuncay; Öztürk, Ersin; Egeli, Ünal; Çeçener, Gülşah; Alemdar, Adem; Evrensel, Türkkan; DELİGÖNÜL, ADEM; AKSOY, SEÇİL; TEZCAN, GÜLÇİN; TUNCA, BERRİN; Kanat, Özka; ÇUBUKÇU, ERDEM; YILMAZLAR, AHMET TUNCAY; EGELİ, ÜNAL; ÇEÇENER, GÜLŞAH; ALEMDAR, ADEM; EVRENSEL, TÜRKKAN; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Diş Hekimliği Fakültesi/Temel Bilimler Bölümü.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü.; 0000-0002-6400-4911; 0000-0002-5956-8755; 0000-0002-1619-6680; 0000-0001-8593-5101; 0000-0001-7904-883X; 0000-0002-3820-424X; HIZ-7332-2022; AAH-1420-2021; AAH-3843-2020; ESM-4544-2022; JDG-0330-2023; ABI-6078-2020; CYM-0930-2022; ETP-1691-2022; CKK-3621-2022; AAP-9988-2020; EXZ-0745-2022
Background and Aim: In 10-30% of colorectal cancer (CRC) patients, toxic reactions occur after fluoropyrimidine-based chemotherapy. A dihydropyridine dehydrogenase (DPYD) gene variant, c.1905 + 1G>A, leads to intolerance to fluoropyrimidines. Due to the low frequency of this variant in many populations, the prevalence of fluoropyrimidine-induced hematologic side effects in CRC patients with the c.1905 + 1G>A variant is unclear. In this study, we investigated the prevalence of the DPYD c.1905 + 1 variants in a Turkish CRC cohort and the potential effects of these variants on fluoropyrimidine-induced hematologic side effects.Materials and Methods: The DPYD c.1905 + 1 variant was genotyped using polymerase chain reaction-restriction fragment length polymorphism analysis and confirmed by Sanger sequencing in peripheral blood samples of 100 CRC patients who received fluoropyrimidine-based chemotherapy and 60 healthy volunteers. The association of c.1905 + 1 variants with susceptibility to hematologic side effects was evaluated.Results: The DPYD c.1905 + 1G>A variant was more common in the CRC group than in the healthy control group (p = 0.001). The presence of the c.1905 + 1G>A variant was associated with thrombocytopenia (p = 0.039) and anemia (p = 0.035). CRC patients with fluoropyrimidine-induced anemia had shorter disease-free survival than CRC patients without fluoropyrimidine-induced anemia (p = 0.0009).Conclusions: Before administering fluoropyrimidine-based chemotherapy, genetic screening for the DPYD c.1905 + 1G>A variant should be performed with the aim of preventing anemia and anemia-induced complications in CRC patients.
Inhibitory effects of olea europaea leaf extract on mesenchymal transition mechanism in glioblastoma cells
(Routledge, 2021-04-24) Mutlu, Melis; Tunca, Berrin; Aksoy, Seçil; Tekin, Çağla; Egeli, Ünal; Çeçener, Gülşah; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; 0000-0001-7904-883X; 0000-0002-1619-6680; 0000-0002-3760-9755; 0000-0002-3820-424X; AAH-1420-2021; ABI-6078-2020; AAH-8540-2021; 57212065763; 6602965754; 57200365076; 57214764024; 55665145000; 6508156530
Background: Glioblastoma (GB) is the most aggressive form of brain tumor. Despite the current treatment methods, the survival rate of patients is very low. Therefore, there is a need to develop new therapeutic agents. The migration and invasion capacity of GB cells is related to mesenchymal transition (MT) mechanism. Materials and Methods: The effect of OLE on MT was determined by analysis of the Twist, Snail, Zeb1, N-cadherin and E-cadherin genes in the EMT mechanism. The effect of OLE on cell migration was determined by wound healing test. Results: 2 mg/ml OLE reduced Twist, Snail, Zeb1 and N-cadherin expression and the combination of OLE + TMZ (2 mg/ml OLE + 350 mM TMZ) increased E-cadherin and reduced Twist, Zeb1 and N-cadherin. In addition, co-treatment with OLE increased TMZ-induced anti-invasion properties thought suppressing transcription factors of MT mechanism. Conclusion: OLE can enhance the anti-MT activities of TMZ against GB and provide strong evidence that combined treatment with OLE and TMZ has the potential to be an effective alternative approach in GB therapy.
Kodlama yapmayan uzun RNA'ların kolon tümörlerinde prognoz açısından öneminin araştırılması
(Bursa Uludağ Üniversitesi, 2019-09-13) Aksoy, Seçil; Tunca, Berrin; Bursa Uludağ Üniversitesi/Sağlık Bilimleri Enstitüsü/Tıbbi Biyoloji Anabilim Dalı.
Kodlama Yapmayan Uzun RNA' ların Kolon Tümörlerinde Prognoz Açısından Öneminin Araştırılması Erken evre kolon kanserlerinde (KK) tedavi protokollerini belirlemede ve nüksü öngörmede mevcut parametreler yetersiz kalmaktadır. Ayrıca kötü prognostik faktörleri olmayan ancak nüks potansiyeli belirlenen erken evre KK'ların standart tedavilere verecekleri yanıt da bilinmemektedir. Mevcut tez çalışmasında kötü prognostik faktörleri bulunmayan erken evre KK'larda prognozu belirlemede kullanılabilecek parametrelerin tanımlanması ve belirlenmesi öngörülen parametrelerden yararlanılarak adjuvan tedavi planlanacak tümörlerde, ilaç direnç durumunun değerlendirilmesi amaçlanmıştır. Mevcut tez çalışmasında, 2005-2013 yılları arasında erken evre (T1-3N0M0), herhangi bir kötü prognostik faktörü bulunmayan, KK tanısı alan 126 hasta değerlendirildi. Nüks potansiyeli belirlenen hastaların tedaviye verecekleri yanıtı öngörmek için 5FU'ya dirençli HT29FUR hücreleri oluşturularak, bu hücrelerin metastatik özellikleri ve tümör dokularda incelenen parametreler değerlendirildi. İlaç direnç gelişimi ve metastaz arasındaki olası sinerji, fonksiyonel analizler (yara iyileştirmesi ve koloni oluşumu) ile incelendi. 126 hastanın takip sırasında 21'inde nüks gelişimi belirlendi. MACC1'in ve MALAT1'in yüksek, PTENP1'in ve NM23-H1'in ise düşük ekspresyonları ve tümör tomurcuklanması varlığı, erken evre KK tümörlerinin nüks gelişimi ile ilişkili olarak belirledi (p<0.05). İlaç direncini öngörmek için oluşturulan HT-29FUR hücrelerinde de MALAT1'in yüksek, PTENP1'in düşük ekspresyonu tanımlandı. Bununla birlikte fonksiyonel analizler ile ilaç direnci oluşumu sırasında hücrelerin metastaz yetenekleri de kazandıkları kanıtlandı. Sonuç olarak, MALAT1 ve PTENP1'in erken evre KK'larda nüks potansiyelini belirlemede ideal birer biyobelirteç adayı oldukları ve bu tip tümörlerde yeni tedavi stratejilerinin geliştirilmesinde bu LncRNA'ların hücre içinde hedeflenerek tedavi sürecine katkı sağlayabileceklerinin mümkün olabileceği belirlendi.
Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas
(Assoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevo, 2020) Tezcan, Gülçin; Argadal, Ömer Gökay; Mutlu, Melis; Aksoy, Seçil; Kocaeli, Hasan; Tunca, Berrin; Civan, Muhammet Nafi; Egeli, Ünal; Cecener, Gülşah; Bekar, Ahmet; Taşkapılıoğlu, M. Özgür; Tekin, Çağla; Tezcan, Gülçin; Tolunay, Şahine; BursaUludağ Üniversitesi/Tıp Fakültesi/Nöroşirürji Anabilim Dalı.; 0000-0002-3760-9755; 0000-0002-1619-6680; 0000-0001-7904-883X; 0000-0002-3820-424X; 0000-0001-5472-9065; FPB-0403-2022; CCA-2925-2022; FDK-3229-2022; CMP-5265-2022; CGB-7869-2022; GDC-6329-2022; AAH-3843-2020; AAI-1612-2021; 57214765002; 57212065763; 57193933334; 6603500567; 6602965754; 57214763395; 55665145000; 6508156530; 6603677218; 25936798300; 57214764024; 25650627600
Primary glioblastoma (GB) is the most aggressive type of brain tumors. While mutations in isocitrate dehydrogenase (IDH) genes are frequent in secondary GBs and correlate with a better prognosis, most primary GBs are IDH wild-type. Recent studies have shown that the long noncoding RNA metastasis associated lung adenocarcinoma transcript-1 (MALAT1) is associated with aggressive tumor phenotypes in different cancers. Our aim was to clarify the prognostic significance of MALAT1 in IDH1/2 wild-type primary GB tumors. We analyzed IDH1/2 mutation status in 75 patients with primary GB by DNA sequencing. The expression of MALAT1 was detected in the 75 primary GB tissues and 5 normal brain tissues using reverse transcription quantitative PCR (RT-qPCR). The associations between MALAT1 expression, IDH1/2 mutation status, and clinicopathological variables of patients were determined. IDH1 (R132H) mutation was observed in 5/75 primary GBs. IDH2 (R172H) mutation was not detected in any of our cases. MALAT1 expression was significantly upregulated in primary GB vs. normal brain tissues (p = 0.025). Increased MALAT1 expression in IDH1/2 wild-type primary GBs correlated with patient age and tumor localization (p = 0.032 and p = 0.025, respectively). A multivariate analysis showed that high MALAT1 expression was an unfavorable prognostic factor for overall survival (p = 0.034) in IDH1/2 wild-type primary GBs. High MALAT1 expression may have a prognostic role in primary GBs independent of IDH mutations.
The orange-red pigment from Penicillium mallochii: Pigment production, optimization, and pigment efficacy against Glioblastoma cell lines
(Elsevier, 2019-11-25) Bouhri, Youcef; Aşkun, Tülin; Deniz, Görkem; Tunca, Berrin; Aksoy, Seçil; Mutlu, Melis; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.; 0000-0002-1619-6680; 0000-0002-3760-9755; FPB-0403-2022; 6602965754; 57193933334; 57212065763
The red-orange pigment producer strain Penicillium mallochii (TACB-16) used in this study was isolated from beech tree bark in Balikesir, Turkey, and was identified by molecular methods (P. mallochii Genbank accession number: MG591446). P. mallochii Rivera, Urb & Seifert was first isolated from the caterpillars Rothschildia lebeau and Citheronia lobesis on Costa Rica and is a new record for Turkey. Little is known of this fungus. In this study, the pigment production of P. mallochii on different media was characterised, and the factors affecting the pigment production and efficacy against the human GB cell line T98G cell viability/cytotoxicity were inspected. The results showed that the pigment was resistant to different temperatures and pH values. The -250 base pair of the ITS region was sequenced and submitted to the Genbank. The blast result of the sequence showed that our isolate displayed maximum similarity (100%) to P. mallochii. Glioblastoma (grade-IV astrocytoma, WHO) is the most lethal subtype of glioma and the survival rate of GB patients is still low. Our results suggest that the pigment exhibits anti-proliferative effects on the T98G cell line. The present study is the first to assess the cytotoxic effect of the pigment on the survival of GB cells. Further studies and validations are needed, but we suggest that the pigment might be used for in vitro and in vivo studies, food industry and for future medical drug studies.